

Table S1. Calculating rules of The Work Productivity and Activity Impairment Questionnaire - General Health (WPAI-GH)

	Calculating rules
Absenteeism	$Q2 / (Q2 + Q4) * 100$
Presenteeism	$Q5 / 10 * 100$
Overall work impairment	$(Q2 / (Q2 + Q4) + (1 - Q2 / (Q2 + Q4)) * Q5 / 10) * 100$
Activity impairment	$Q6/10*100$

Table S2. Calculating rules of Treatment Satisfaction Questionnaire for Medication (WPAI-GH)

	Calculating rules (without missing value)	Calculating rules (with one missing value)
Effectiveness	$(Q1 + Q2 + Q3 - 3) / 18 * 100$	$(\text{Sum of answered Qs} - 2) / 12 * 100$
Side effects	$Q4 = \text{'No'}$, Score = 100; $(Q5 + Q6 + Q7 + Q8 - 4) / 16 * 100$	$(\text{Sum of answered Qs} - 3) / 12 * 100$
Convenience	$(Q9 + Q10 + Q11 - 3) / 18 * 100$	$(\text{Sum of answered Qs} - 2) / 12 * 100$ Q12 or Q13 missed:
Global Satisfaction	$(Q12 + Q13 + Q14 - 3) / 14 * 100$	$(\text{Sum of answered Qs} - 2) / 10 * 100$; Q14 missed: $(\text{Sum of answered Qs} - 2) / 8 * 100$

Table S3. Stratified Analysis of AT Group Based on Monotherapy and Combination Therapy of the proportions of patients with ≥ 6 -point improvement in HIT-6

	AT (N=88)	monotherapy (N=49)	Concomitant therapy(N=39)
All patients, No. (%)	30 (34.1)	18(36.7)	12(30.8)
Migraine type, No. / total No. (%)			
Without aura	22/69 (31.9)	15/41(36.6)	7/28(25.0)
With aura	5/10 (50.0)	2/4(50.0)	3/6(50.0)
Chronic	3/8 (37.5)	1/3(33.3)	2/5(40.0)
Others	0/1 (0)	0/1 (0)	0/0 (NA)
MMD, No. / total No. (%)			
≤ 3	6/26 (23.1)	4/18(22.2)	2/8(25.0)
[4, 14]	22/48 (45.8)	13/27(48.2)	9/21(42.9)
≥ 15	2/14 (14.3)	1/4(25.0)	1/10(10.0)
Menstrually-related migraine, No. / total No. (%)	20/53 (37.7)	12/29(41.4)	8/24(33.3)